Process for producing target cell lysis factor and uses therewith

Abstract

Target Cell Lysis Factor (TCLF) is produced by exposing a human cell line capable of producing TCLF to a TCLF inducer to induce TCLF production, and collecting and purifying the accumulated TCLF. The TCLF which is produced includes lymphotoxin and human Tumor Necrosis Factor (hTNF). The hTNF may be separated and purified. The human cell lines are preferably human leucocyte and human lymphoblastoid lines, such as BALL-1, TALL-1, NALL-1 Namalwa, MOLT-3, Mono-1, M-7002, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM, DND-41 and CCRF-SB, as well as human cell lines which are obtainable by transforming normal human monocytes, or granulocytes. All of these human cell lines are multipliable by implanting them in a non-human warm-blooded animal, or alternatively, allowing them to multiply in a conventional-type diffusion chamber by which the nutrient body fluid of a non-human warm-blooded animal is supplied to them.

Description

Claims

1. A process for producing human Target Cell Lysis Factor (TCLF), comprising:

implanting a human cell line selected from the group of cell lines consisting of BALL-1, TALL-1, NALL-1, Namalwa, MOLT-3, Mono-1, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM, DND-41, and CCFR-SB in a non-human warm-blooded animal;

feeding the animal to allow said human cell line to utilize the nutrient body fluid of the animal for its multiplication;

exposing the multiplied human cells to a TCLF inducer under conditions appropriate to induce the accumulation of a substantial amount of TCLF by said cells; and

recovering the accumulated TCLF.

2. A process in accordance with claim 1, wherein said exposing and recovering steps comprise:

extracting and disaggregating the human cell line tumor formed in the animal to obtain the multiplied human cells;

exposing the multiplied human cells to an effective amount of TCLF inducer on an in vitro culture medium under conditions appropriate to induce the accumulation of a substantial amount of TCLF; and

recovering the accumulated TCLF from said culture.

3. A process in accordance with claim 1, wherein said TCLF inducer is a member selected from the group consisting of virus, nucleic acid, nucleotide, lectin, mitogen and endotoxin.

4. A process in accordance with claim 1, wherein said TCLF inducer is phytohaemagglutinin or concanavalin A.

5. A process in accordance with claim 1, wherein said TCLF is a glycoprotein with a molecular weight in the range of 1.times.10.sup.4 -1.times.10.sup.5 daltons and a saccharide content in the range of 5-45%.

6. A process in accordance with claim 1, wherein the TCLF contains at least one member of specimens having a molecular weight of about 1.times.10.sup.4 -2.times.10.sup.4 daltons, about 3.5.times.10.sup.4 -5.times.10.sup.4 daltons or about 7.times.10.sup.4 -9.times.10.sup.4 daltons.

7. A process as set forth in claim 1, wherein said TCLF contains a member selected from the group consisting of lymphotoxin, human Tumor Necrosis Factor (hTNF) and a mixture thereof.

8. A process for producing human Target Cell Lysis Factor (TCLF), comprising:

suspending a human cell line selected from the group of cell lines consisting of BALL-1, TALL-1, NALL-1, Namalwa, MOLT-3, Mono-1, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM, DND-41 and CCRF-SB in a diffusion chamber in which the nutrient body fluid of a non-human warm-blooded animal may be supplied to said human cell line;

embedding or placing said chamber in or on a non-human warm-blooded animal in a manner such that the nutrient body fluid of said animal is supplied to the cell line within said chamber;

feeding the animal to allow said human cell line to utilize said nutrient body fluid for its multiplication;

exposing the multiplied human cells to a TCLF inducer under conditions appropriate to induce the accumulation of a substantial amount of TCLF; and

recoving the accumulated TCLF.

9. A process in accordance with claim 8, wherein said exposing and recovering steps comprise:

harvesting the multiplied human cells from said diffusion chamber;

exposing the harvested multiplied human cells to an effective amount of TCLF inducer on an in vitro culture medium under conditions appropriate to induce the accumulation of a substantial amount of TCLF; and

recovering the accumulated TCLF from said culture.

10. A process in accordance with claim 8, wherein said TCLF inducer is a member selected from the group consisting of virus, nucleic acid, nucleotide, lectin, mitogen and endotoxin.

11. A process in accordance with claim 8, wherein said TCLF inducer is phytohaemagglutinin or concanavalin A.

12. A process in accrdance with claim 8, wherein said TCLF is a glycoprotein with a molecular weight in the range of 1.times.10.sup.4 -1.times.10.sup.5 daltons and a saccharide content in the range of 5-45%.

13. A process in accordance with claim 8, wherein the TCLF contains at least one member of specimens having a molecular weight of about 1.times.10.sup.4 -2.times.10.sup.4 daltons, about 3.5.times.10.sup.4 -5.times.10.sup.4 daltons or about 7.times.10.sup.4 -9.times.10.sup.4 daltons.

14. A process as set forth in claim 8, wherein said TCLF contains a member selected from the group consisting of lymphotoxin, human Tumor Necrosis Factor (hTNF) and a mixture thereof.

15. A process for producing human Tumor Necrosis Factor (nTNF), comprising:

culturing a human cell line capable of producing hTNF in the presence of an effective amount of a TNF inducer under conditions appropriate to induce the accumulation of a substantial amount of hTNF; and

recovering hTNF.

16. A process in accordance with claim 15, wherein said culturing step comprises:

implanting a human cell line capable of producing hTNF in a non-human warm-blooded animal;

feeding the animal to allow said human cell line to utilize the nutrient body fluid of the animal for its multiplication; and

exposing the multiplied human cells to a TNF inducer under conditions appropriate to induce the accumulation of a substantial amount of hTNF.

17. A process in accordance with claim 15, wherein said culturing step comprises;

suspending a human cell line capable of producing hTNF in a diffusion chamber in which the nutrient body fluid of a non-human warm-blooded animal may be supplied to said human cell line;

embedding or placing said chamber in or on a non-human warm-blooded animal in a manner such that nutrient body fluid of said animal is supplied to the cell line within said chamber;

feeding the animal to allow said human cell line to utilize said nutrient body fluid for its multiplication; and

exposing the multiplied human cells to TNF inducer under conditions appropriate to induce the accumulation of a substantial amount of hTNF.

18. A process as set forth in claim 16, wherein said exposing and recovering steps comprise:

extracting and disaggregating the human cell line tumor, formed in the animal, to obtain the multiplied human cells;

exposing the multiplied human cells to an effective amount of TNF inducer on an in vitro culture medium under conditions appropriate to induce the accumulation of a substantial amount of hTNF; and

recovering the accumulated hTNF from said culture.

19. A process in accordance with claim 15, wherein said exposing and recovering steps comprise:

harvesting the multiplied human cells from said diffusion chamber;

exposing the harvested multiplied human cells to an effective amount of TNF inducer on an in vitro culture under conditions appropriate to induce the accumulation of a substantial amount of hTNF; and

recovering the accumulated hTNF from said culture.

20. A process in accordance with claim 15, wherein said human cell line is a human lymphoblastoid line.

21. A process in accordance with claim 15, wherein said human cell line is a member selected from the group of cell lines consisting of BALL-1, NALL-1, TALL-1, Namalwa, MOLT-3, Mono-1, B-7101, JBL, EBV-Sa, EBV-Wa, EBV-HO, BALM 2, CCRF-CEM and CCFR-CB.

22. A process in accordance with claim 15, wherein said TNF inducer is a member selected from the group consisting of virus, nucleic acid, nucleotide, lectin, mitogen and endotoxin.

23. A process in accordance with claim 15, wherein said TNF inducer is phytohaemagglutinin or concavalin A.